Surrozen reports Q1 2026 financial results
Cash at $106.9M. On track for SZN-8141 IND submission H2 2026. Net loss $127.5M.
See the latest news and media coverage for Surrozen. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing Wnt-based ophthalmic therapies
surrozen.comLast updated
In short: Surrozen announced a strategic research collaboration for lung fibrosis treatments and planned a 2026 IND filing for its eye drug SZN-8141.
Cash at $106.9M. On track for SZN-8141 IND submission H2 2026. Net loss $127.5M.
Pipeline advances with IND submission for SZN-8141 planned for H2 2026. Receives $5M milestone from Boehringer Ingelheim. Strengthens leadership. Cash at $89.2M; net loss $242M.
Cash stands at $81.3M. Appoints Andrew Maleki as CFO. Advances ophthalmology pipeline with IND for SZN-8141 planned in 2026.
Appoints Daniel Chao as VP of Clinical Development, forms Clinical Advisory Board, progresses ophthalmology pipeline, reports $90.4M cash.
Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Surrozen, Inc. before investing...
Research collaboration to leverage Surrozen’s antibody research capabilities and expertise to discover a potential first in class treatment for patients with Idiopathic Pulmonary Fibrosis SOUTH...
Surrozen remains focused on advancing a new generation of ophthalmology therapeutics that are built on a foundation of Wnt pathway biology. Surrozen's pipeline leverages its...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or...
Track Surrozen and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Surrozen and other trending companies.